Patents by Inventor Michael John Green

Michael John Green has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11718628
    Abstract: Provided herein are compounds comprising a three-ring core, such as compounds of Formula (X), Formula (X-A), Formula (X-Ai), Formula (X-B), Formula (X-Bi), Formula (Z), Formula (Z-A), Formula (Z-Ai), Formula (Z-B), Formula (Z-Bi), Formula (I), Formula (I-A), Formula (I-Ai), Formula (I-B), and Formula (I-Bi), and pharmaceutically acceptable salts, solvates, tautomers, isotopes, or isomers thereof. Also provided herein are methods of inhibiting a component of the sterol regulatory element binding protein (SREBP) pathway, such as an SREBP or SREBP cleavage activating protein (SCAP), using these compounds, or pharmaceutically acceptable salts, solvates, tautomers, isotopes, or isomers thereof. Further provided are methods of treating a disorder in a subject in need thereof, such as liver disease, non-alcoholic steatohepatitis, insulin resistance, or cancer.
    Type: Grant
    Filed: July 27, 2020
    Date of Patent: August 8, 2023
    Assignee: CAPULUS THERAPEUTICS, LLC
    Inventors: Michael John Green, Barry Patrick Hart
  • Publication number: 20230225468
    Abstract: An adjustable mount and handle to support an umbrella onto a tube is disclosed. The present invention permits a user attach the umbrella to a tube or post and quickly and easily adjust the angle at any time. Thus, an individual can be shaded by the umbrella without having to manually hold the umbrella themselves.
    Type: Application
    Filed: January 18, 2022
    Publication date: July 20, 2023
    Inventor: Michael John Green
  • Publication number: 20230147993
    Abstract: Provided herein are compounds comprising a four-ring core, such as compounds of Formula (I) and Formula (II), and pharmaceutically acceptable salts, solvates, tautomers, isotopes, or isomers thereof. Also provided herein are methods of inhibiting a component of the sterol regulatory element binding protein (SREBP) pathway, such as an SREBP or SREBP cleavage activating protein (SCAP), using these compounds, or pharmaceutically acceptable salts, solvates, tautomers, isotopes, or isomers thereof. Further provided are methods of treating a disorder in a subject in need thereof, such as liver disease, non-alcoholic steatohepatitis, insulin resistance, or cancer.
    Type: Application
    Filed: May 12, 2022
    Publication date: May 11, 2023
    Inventors: Michael John GREEN, Barry Patrick HART
  • Publication number: 20220356170
    Abstract: Provided herein is the compound (3-chloro-4-(4-(2-(2-hydroxypropan-2-yl)pyridin-4-yl)thiophen-2-yl)phenyl)(4-hydroxypiperidin-1-yl)methanone (Compound 1), and pharmaceutically acceptable salts, solvates, tautomers, isotopes, or isomers thereof. Also provided herein are methods of inhibiting a component of the sterol regulatory element binding protein (SREBP) pathway, such as an SREBP or SREBP cleavage activating protein (SCAP), using Compound 1, or a pharmaceutically acceptable salt, solvate, tautomer, isotope, or isomer thereof. Further provided are methods of treating a disorder in a subject in need thereof, such as liver disease, non-alcoholic steatohepatitis, insulin resistance, or cancer.
    Type: Application
    Filed: May 12, 2022
    Publication date: November 10, 2022
    Inventors: Michael John GREEN, Barry Patrick HART
  • Patent number: 11485725
    Abstract: The present invention relates to a group of 1-[(E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]-2,3-dihydropyridin-6-one (piperlongumine) derivatives, analogs and pharmaceutically acceptable salts thereof. The present invention also relates to processes for preparing the same; a pharmaceutical composition and formulation containing a derivative of piperlongumine; and use of the derivatives and analogs for treating cancer.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: November 1, 2022
    Assignee: Auransa Inc.
    Inventors: Andrew Asher Protter, Michael John Green, Hak Jin Chang, Son Minh Pham, Sarvajit Chakravarty, Gregory R. Luedtke, Pek Yee Lum
  • Publication number: 20220056018
    Abstract: Provided herein are compounds comprising a three-ring core, such as compounds of Formula (I), Formula (I-i), Formula (I-A), Formula (I-A-i), Formula (I-A-i-1), Formula (I-B), Formula (I-B-i), Formula (I-B-i-1), Formula (II), Formula (II-i), Formula (II-A), Formula (II-A-i), Formula (II-A-i-1), Formula (II-B), Formula (II-B-i), and Formula (II-B-i-1) and pharmaceutically acceptable salts, solvates, tautomers, isotopes, or isomers thereof. Also provided herein are methods of inhibiting a component of the sterol regulatory element binding protein (SREBP) pathway, such as an SREBP or SREBP cleavage activating protein (SCAP), using these compounds, or pharmaceutically acceptable salts, solvates, tautomers, isotopes, or isomers thereof. Further provided are methods of treating a disorder in a subject in need thereof, such as liver disease, non-alcoholic steatohepatitis, insulin resistance, or cancer.
    Type: Application
    Filed: July 26, 2021
    Publication date: February 24, 2022
    Inventors: Michael John GREEN, Barry Patrick HART
  • Patent number: 11173144
    Abstract: Adrenergic receptor modulating compounds and methods of using the same are provided. Also provided are methods of treating a subject for a disease or condition associated with an adrenergic receptor including administering a therapeutically effective amount of the subject compound. Aspects of the disclosure include a method of modulating an inflammatory pathway in a cell, such as the production of TNF-alpha in the cell. The method can include contacting a cell with ?1-selective adrenergic receptor modulating compound to selectively activate a cAMP pathway over a beta-arrestin pathway in the cell. Pharmaceutical compositions and kits which include the subject compounds are provided.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: November 16, 2021
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Mehrdad Shamloo, Alam Jahangir, Bitna Yi, Andrew Kelley Evans, Michael John Green
  • Publication number: 20210317140
    Abstract: The present application discloses compounds that are inhibitors of Btk, compounds that are inhibitors of PI3K?, and compounds that are dual inhibitors of both Btk and PI3K?. Also described are methods for synthesizing such inhibitors and methods for using such inhibitors for the treatment of diseases wherein inhibition of Btk and PI3K? provides a therapeutic benefit to a patient having the disease.
    Type: Application
    Filed: October 17, 2014
    Publication date: October 14, 2021
    Applicant: Medivation Technologies, Inc.
    Inventors: Roopa RAI, Sarvajit CHAKRAVARTY, Michael John GREEN, Son Minh PHAM, Brahman PUJALA, Anil Kumar AGARWAL, Anjan Kumar NAYAK, Sweta KHARE, Rambabu GUGULOTH, Nitin Atmaram RANDIVE
  • Publication number: 20210198235
    Abstract: The present invention relates to a group of 1-[(E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]-2,3-dihydropyridin-6-one (piperlongumine) derivatives, analogs and pharmaceutically acceptable salts thereof. The present invention also relates to processes for preparing the same; a pharmaceutical composition and formulation containing a derivative of piperlogumine; and use of the derivatives and analogs for treating cancer.
    Type: Application
    Filed: November 14, 2018
    Publication date: July 1, 2021
    Inventors: Andrew Asher PROTTER, Michael John GREEN, Hak Jin CHANG, Son Minh PHAM, Sarvajit CHAKRAVARTY, Gregory R. LUEDTKE
  • Publication number: 20210047340
    Abstract: Provided herein are compounds comprising a three-ring core, such as compounds of Formula (X), Formula (X-A), Formula (X-Ai), Formula (X-B), Formula (X-Bi), Formula (Z), Formula (Z-A), Formula (Z-Ai), Formula (Z-B), Formula (Z-Bi), Formula (I), Formula (I-A), Formula (I-Ai), Formula (I-B), and Formula (I-Bi), and pharmaceutically acceptable salts, solvates, tautomers, isotopes, or isomers thereof. Also provided herein are methods of inhibiting a component of the sterol regulatory element binding protein (SREBP) pathway, such as an SREBP or SREBP cleavage activating protein (SCAP), using these compounds, or pharmaceutically acceptable salts, solvates, tautomers, isotopes, or isomers thereof. Further provided are methods of treating a disorder in a subject in need thereof, such as liver disease, non-alcoholic steatohepatitis, insulin resistance, or cancer.
    Type: Application
    Filed: July 27, 2020
    Publication date: February 18, 2021
    Inventors: Michael John GREEN, Barry Patrick HART
  • Publication number: 20200237724
    Abstract: Adrenergic receptor modulating compounds and methods of using the same are provided. Also provided are methods of treating a subject for a disease or condition associated with an adrenergic receptor including administering a therapeutically effective amount of the subject compound. Aspects of the disclosure include a method of modulating an inflammatory pathway in a cell, such as the production of TNF-alpha in the cell. The method can include contacting a cell with ?1-selective adrenergic receptor modulating compound to selectively activate a cAMP pathway over a beta-arrestin pathway in the cell. Pharmaceutical compositions and kits which include the subject compounds are provided.
    Type: Application
    Filed: May 12, 2017
    Publication date: July 30, 2020
    Inventors: Mehrdad Shamloo, Alam Jahangir, Bitna Yi, Andrew Kelley Evans, Michael John Green
  • Publication number: 20170137410
    Abstract: Fused cycloalkyl-pyrimidine compounds that are kinase inhibitors, such as multi-kinase inhibitors, are provided. The compounds may be used in a method of treating cancer. Pharmaceutical compositions containing a fused cycloalkyl-pyrimidine compound and a pharmaceutically acceptable carrier are also provided, as are kits containing a fused cycloalkyl-pyrimidine compound or salt thereof and instructions for use, e.g., in a method of treating cancer.
    Type: Application
    Filed: June 26, 2015
    Publication date: May 18, 2017
    Applicant: Medivation Technologies, Inc
    Inventors: Sarvajit CHAKRAVARTY, Roopa RAI, Michael John GREEN, Amantullah ANSARI, Anil Kumar AGARWAL
  • Patent number: 9550782
    Abstract: Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are antagonists of the adrenergic receptor ?2A. The compounds may also bind to and are an antagonist of the adrenergic receptor ?2B; or the compounds are not antagonists of the adrenergic receptor ?2B and the compounds are administered in conjunction with a second agent that reduces, or is expected to reduce, blood pressure in an individual. The compounds may find use in therapy, e.g., to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. Use of the compounds to treat type 2 diabetes is particularly described.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: January 24, 2017
    Assignee: MEDIVATION TECHNOLOGIES, INC.
    Inventors: Andrew Asher Protter, Sarvajit Chakravarty, Rajendra Parasmal Jain, Michael John Green
  • Patent number: 9527854
    Abstract: Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are adrenergic receptor ?2B antagonists. The compounds may also bind to and antagonize adrenergic receptor ?1B. The compounds may find use in therapy, e.g., to (i) reduce blood pressure and/or (ii) promote renal blood flow and/or (iii) decrease or inhibit sodium reabsorption. The compounds may also be used to treat diseases or conditions that are, or are expected to be, responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular and renal disorders is particularly described.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: December 27, 2016
    Assignee: Medivation Technologies, Inc.
    Inventors: Andrew Asher Protter, Sarvajit Chakravarty, Rajendra Parasmal Jain, Michael John Green
  • Patent number: 9499519
    Abstract: Fused pyrimidine compounds as kinase inhibitors, such as multi-kinase inhibitors, are provided. Fused pyrimidine compounds as IGF-IR inhibitors are provided. Fused pyrimidine compounds that are inhibitors of Trk receptors (e.g., Trk A, Trk B and Trk C) are provided also. The compounds may be used in a method of treating cancer. Pharmaceutical compositions containing a fused pyrimidine compound and a pharmaceutically acceptable carrier are also provided, as are kits containing a fused pyrimidine compound or salt thereof and instructions for use, e.g., in a method of treating cancer.
    Type: Grant
    Filed: December 26, 2013
    Date of Patent: November 22, 2016
    Assignee: MEDIVATION TECHNOLOGIES, INC.
    Inventors: Sarvajit Chakravarty, Roopa Rai, Michael John Green, Amantullah Ansari
  • Publication number: 20160272645
    Abstract: The present application discloses compounds that are inhibitors of Btk, compounds that are inhibitors of PI3K?, and compounds that are dual inhibitors of both Btk and PI3K?. Also described are methods for synthesizing such inhibitors and methods for using such inhibitors for the treatment of diseases wherein inhibition of Btk and PI3K? provides a therapeutic benefit to a patient having the disease.
    Type: Application
    Filed: October 17, 2014
    Publication date: September 22, 2016
    Applicant: Medivation Technologies, Inc.
    Inventors: Roopa RAI, Sarvajit CHAKRAVARTY, Michael John GREEN, Son Minh PHAM, Brahmam PUJALA, Anil Kumar AGARWAL, Anjan Kumar NAYAK, Sweta KHARE, Rambabu GUGULOTH, Nitin Atmaram RANDIVE
  • Patent number: 9422267
    Abstract: The present invention provides fused pyrimidine compounds of the general Formula (I): or a salt thereof, wherein the variables are as defined in the specification. Fused pyrimidine compounds of the general Formula (I) are provided as kinase inhibitors, such as multi-kinase inhibitors. In one aspect, fused pyrimidine compounds of the general Formula (I) are provided as IGF-IR inhibitors. The compounds may be used in a method of treating cancer. Pharmaceutical compositions containing a fused pyrimidine compounds of the general Formula (I) and a pharmaceutically acceptable carrier are also provided, as are kits containing a fused pyrimidine compound of the general Formula (I) or salt thereof and instructions for use, e.g., in a method of treating cancer.
    Type: Grant
    Filed: December 26, 2013
    Date of Patent: August 23, 2016
    Assignee: Medivation Technologies, Inc.
    Inventors: Sarvajit Chakravarty, Roopa Rai, Michael John Green
  • Publication number: 20160068513
    Abstract: Fused pyrimidine compounds as kinase inhibitors, such as multi-kinase inhibitors, are provided. Fused pyrimidine compounds as IGF-IR inhibitors are provided. Fused pyrimidine compounds that are inhibitors of Trk receptors (e.g., Trk A, Trk B and Trk C) are provided also. The compounds may be used in a method of treating cancer. Pharmaceutical compositions containing a fused pyrimidine compound and a pharmaceutically acceptable carrier are also provided, as are kits containing a fused pyrimidine compound or salt thereof and instructions for use, e.g., in a method of treating cancer.
    Type: Application
    Filed: December 26, 2013
    Publication date: March 10, 2016
    Applicant: MEDIVATION TECHNOLOGIES, INC.
    Inventors: Sarvajit CHAKRAVARTY, Roopa RAI, Michael John GREEN, Amantullah ANSARI
  • Publication number: 20150315188
    Abstract: Hydrogenated pyrido[4,3-b]indoles and pyrido[3,4-b]indoles are described. The compounds may bind to and are adrenergic receptor ?2B antagonists. The compounds may also bind to and antagonize adrenergic receptor ?1B. in The compounds may find use in therapy, e.g., to (i) reduce blood pressure and/or (ii) promote renal blood flow and/or (iii) decrease or inhibit sodium reabsorption. The compounds may also be used to treat diseases or conditions that are, or are expected to be, responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular and renal disorders is particularly described.
    Type: Application
    Filed: March 15, 2013
    Publication date: November 5, 2015
    Inventors: Andrew Asher PROTTER, Sarvajit CHAKRAVARTY, Michael John GREEN
  • Publication number: 20150266884
    Abstract: Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are adrenergic receptor ?2B antagonists. The compounds may also bind to and antagonize adrenergic receptor ?1B. The compounds may find use in therapy, e.g., to (i) reduce blood pressure and/or (ii) promote renal blood flow and/or (iii) decrease or inhibit sodium reabsorption. The compounds may also be used to treat diseases or conditions that are, or are expected to be, responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular and renal disorders is particularly described.
    Type: Application
    Filed: March 6, 2015
    Publication date: September 24, 2015
    Inventors: Andrew Asher PROTTER, Sarvajit CHAKRAVARTY, Rajendra Parasmal JAIN, Michael John GREEN